Our Focus

We are a clinical stage pharmaceutical company delivering novel therapies for hearing loss.

Through the use of proprietary therapeutics and drug delivery technologies, we are building a pipeline of advanced treatments in a field with large unmet needs and no approved therapies.

Our lead candidate, LPT99, reached the clinic in December 2018.

Executive Team

Hugo Peris

Founder and Chief Executive Officer

Charles Limb, MD

Chief Medical Officer

Signe Erickson, PhD

Chief Scientific Officer

Nik Talreja

VP Operations and Finance

Andrew Ayoob, PhD

Director of Product Development

Pablo Villoslada, MD

CLINICAL DEVELOPMENT

Founding Team

Hugo Peris

Justin Hanes, PhD

Eugene de Juan, MD

Board of Directors

Guy Nohra

Chairman

Hugo Peris

Director

Lawrence Fritz

Director

Eugene de Juan

Director

Guy Jean Savoir

Director (SAVOIR CAPITAL)

George Petrocheilos

Director (Camden Partners)

Inner Ear Disorders

Internal and external factors can be responsible for hearing loss. Recent studies have found that peripheral hearing loss impacts family and social interaction as well as work status (Doolittle et al., 2001) and is a significant risk factor for dementia (Livingston, et al., 2017).

With no approved drug therapies, hearing loss is also the most common sensory disorder experienced by humans, and the third-most self-reported health problem in individuals over the age of 65. Worldwide, it is estimated that approximately 500 million people (about one in 13) have disabling hearing loss, with an estimated annual economic burden of $750 billion (Lustig, 2018).

It is an exciting time for translational hearing research. The fundamental advances in our understanding of the molecular mechanisms of many inner ear diseases is just now opening the door to the development of new drugs for currently untreatable conditions.

Technology

Spiral’s immediate opportunity comes from the development of therapies targeting acute hearing loss indications, like chemotherapy-induced hearing loss and noise-induced hearing loss.

Our lead drug candidate, LPT99, is a locally administered otoprotective agent that blocks apoptosis in the ear without interfering with anti-tumor activity of the chemotherapeutic agents that are delivered systemically. LPT99 has shown promising results in several animal models of prevention and treatment of chemotherapy-induced hearing loss, noise-induced hearing loss and other inner ear disorders.

Chronic indications like age-related hearing loss represent a huge unmet need and the largest market opportunity in the field of inner ear therapeutics. We recognize drug delivery as the biggest challenge in the development of effective therapies to address chronic inner ear indications.

By combining our innovative therapies with differentiated drug delivery approaches and a seasoned management team, we aim to become a leader in the rapidly evolving field of inner ear therapeutics.

Careers

Contact

Phone: + 1 (650) 453-0893
Address: 1000 Marina Blvd, Suite 105, Brisbane, CA 94005
Close Menu